Skip to main content
. 2016 Jan 20;2016:4083735. doi: 10.1155/2016/4083735

Figure 3.

Figure 3

STAT3 activation in normal human dermal fibroblasts (white bars, n = 3) and patient fibroblasts with the IL-20RB T104M mutation (dark bars, n = 2) with and without cytokine stimulation: ∗ p < 0.05 between cytokine treated and untreated cells; ∗∗ p < 0.01 and ∗∗∗ p < 0.05 comparing fibroblasts with the T104M IL-20RB mutation versus wild-type cells with the same cytokine treatment (reprinted with copyright permission from Journal of Ocular Pharmacology and Therapeutics). IL-20 was added at 100 or 200 ng/mL and IL-19 and IL-24 were used at 100 ng/mL.